March 18, 2026. 9 articles reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score.
Psychedelics may be no better than antidepressants for depression: studies – ABC News
Article Summary This article reports findings comparing psychedelics to antidepressants for depression treatment, while referencing a cannabinoid study examining cannabis efficacy for depression, anxiety, and PTSD—topics relevant to cannabis clinical practice.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →Cape to Cape for Cannabis nears as organisers urge final registrations – Cannabiz
The article announces an upcoming cannabis industry event in Australia (April 17-20) and calls for final event registrations, potentially relevant to clinicians seeking professional networking or industry updates.
Read more →Two South Jersey parents filed a lawsuit after they say their 10-month-old was found with a …
Parents sued a daycare after their 10-month-old was found with a marijuana vape pen, raising child safety and product accessibility concerns relevant to pediatric exposure prevention.
Read more →Americans Lighten Up About Marijuana While Judging Everything Else – The Fresh Toast
Article Summary This article reports polling data on American attitudes toward marijuana legalization and social acceptance, which may interest clinicians tracking public perception trends relevant to patient populations.
Read more →Former UFC Champ Randy Couture Endorses Active Brand THCV – Combat Press
Former UFC fighter Randy Couture endorses a THCV product brand, highlighting potential applications of this cannabinoid for appetite regulation and stimulating effects that may interest clinicians studying cannabinoid pharmacology.
Read more →Ohio cannabis company sued for using branding owned by LeBron James’ agency
Summary This article covers a trademark dispute between a cannabis retailer and an entertainment agency, illustrating how cannabis businesses must navigate intellectual property law and celebrity brand protection.
Read more →VDOT seeks public input on Shenandoah Valley Rail with Trail study – WHSV
Article Summary Virginia Cannabis Control Authority launches a safe driving campaign related to recreational marijuana, potentially relevant to clinicians advising patients on impairment risks.
Read more →About 19 million people in the US have thought about shooting someone in their lifetime: Study
Article Summary Survey data on U.S. adults’ thoughts about shooting others, with cannabis included as a measured variable alongside firearms, alcohol, and suicide risk factors.
Read more →About 19 million people in the US have thought about shooting someone in their lifetime
Summary This article reports epidemiological data from a survey examining associations between substance use (including cannabis) and violent ideation in US adults, potentially relevant to clinicians assessing patient risk factors.
Read more →Digest-Level Clinical Commentary
Clinical Reflection These digest items reflect the growing maturation and fragmentation of the cannabis medicine field: we’re seeing legitimate therapeutic research (particularly for mood disorders), expanding professional conferences, regulatory standardization efforts, and consumer acceptance tracking, yet simultaneously confronting serious safety gaps like pediatric exposures and evolving questions about cannabinoid specificity that remind us the field remains in its evidential adolescence. As practitioners, we must navigate genuine therapeutic promise in depression and anxiety treatment against a backdrop of inadequate safety infrastructure, trademark disputes suggesting commercialization is outpacing medical rigor, and the concerning signal that cannabis discussions are being pulled into population health surveys on violence and firearm safety without clear mechanistic understanding. The collective picture suggests cannabis medicine is transitioning from fringe to mainstream faster than our clinical evidence base and regulatory frameworks are prepared for, which demands that we remain evidence-
These items reflect several concurrent developments in cannabis medicine and policy: ongoing clinical research into cannabinoid efficacy for psychiatric conditions, regulatory and legal frameworks expanding access while addressing safety concerns, and increasing mainstream commercial activity around cannabis products. The digest suggests a healthcare landscape in transition where cannabis is becoming normalized as a potential therapeutic agent, even as questions remain about relative efficacy compared to established treatments and safety considerations, particularly regarding unintended pediatric exposures and product quality control.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
